Trial · NCT04641975
Results by group118
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 118
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 12/EoT in Mean Number of Micturitions Per 24 Hours for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | -1.62 | Standard Error 0.89 | micturitions per 24 hours | |
| Change From Baseline to Week 12/EoT in Mean Number of Micturitions Per 24 Hours for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | -3.84 | Standard Error 0.89 | micturitions per 24 hours | |
| Change From Baseline to Week 12/EoT in Mean Volume Voided Per 24 Hours for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | Week 12 (without LOCF) | 18.38 | Standard Deviation 33.67 | milliliter (mL)/24 hours |
| Change From Baseline to Week 12/EoT in Mean Volume Voided Per 24 Hours for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | Week 12 (without LOCF) | 24.55 | Standard Deviation 32.32 | milliliter (mL)/24 hours |
| Change From Baseline to Week 12/EoT in Mean Volume Voided Per 24 Hours for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | Week 12 (with LOCF) | 18.38 | Standard Deviation 33.67 | milliliter (mL)/24 hours |
| Change From Baseline to Week 12/EoT in Mean Volume Voided Per 24 Hours for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | Week 12 (with LOCF) | 24.55 | Standard Deviation 32.32 | milliliter (mL)/24 hours |
| Change From Baseline to Week 12/EoT in Maximum Volume Voided (MVV) for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | Week 12 (without LOCF) | 26.00 | Standard Deviation 51.46 | mL |
| Change From Baseline to Week 12/EoT in Maximum Volume Voided (MVV) for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | Week 12 (without LOCF) | 26.38 | Standard Deviation 60.75 | mL |
| Change From Baseline to Week 12/EoT in Maximum Volume Voided (MVV) for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | Week 12 (With LOCF) | 26.00 | Standard Deviation 51.46 | mL |
| Change From Baseline to Week 12/EoT in Maximum Volume Voided (MVV) for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | Week 12 (With LOCF) | 26.38 | Standard Deviation 60.75 | mL |
| Change From Baseline to Week 12/EoT in Mean Number of Daytime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | Week 12 (without LOCF) | -1.29 | Standard Deviation 1.04 | incontinence episodes per 24 hours |
| Change From Baseline to Week 12/EoT in Mean Number of Daytime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | Week 12 (without LOCF) | -1.28 | Standard Deviation 1.73 | incontinence episodes per 24 hours |
| Change From Baseline to Week 12/EoT in Mean Number of Daytime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | Week 12 (with LOCF) | -1.20 | Standard Deviation 1.02 | incontinence episodes per 24 hours |
| Change From Baseline to Week 12/EoT in Mean Number of Daytime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | Week 12 (with LOCF) | -1.09 | Standard Deviation 1.74 | incontinence episodes per 24 hours |
| Change From Baseline to Week 12/EoT in Mean Number of Nighttime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | Week 12 (without LOCF) | -0.64 | Standard Deviation 0.55 | incontinence episodes per 24 hours |
| Change From Baseline to Week 12/EoT in Mean Number of Nighttime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | Week 12 (without LOCF) | -1.34 | Standard Deviation 1.51 | incontinence episodes per 24 hours |
| Change From Baseline to Week 12/EoT in Mean Number of Nighttime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | Week 12 (with LOCF) | -0.64 | Standard Deviation 0.55 | incontinence episodes per 24 hours |
| Change From Baseline to Week 12/EoT in Mean Number of Nighttime Incontinence Episodes Per 24 Hours for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | Week 12 (with LOCF) | -1.34 | Standard Deviation 1.51 | incontinence episodes per 24 hours |
| Change From Baseline to Week 12/EoT in Mean Number of Daytime Micturitions Per 24 Hours for Age Group 5 to <12 Years | Mirabegron (5 to < 12 Years) | Week 12 (without LOCF) | -0.85 | Standard Deviation 2.67 | micturitions per 24 hours |
| Change From Baseline to Week 12/EoT in Mean Number of Daytime Micturitions Per 24 Hours for Age Group 5 to <12 Years | Placebo (5 to < 12 Years) | Week 12 (without LOCF) | -3.21 | Standard Deviation 6.65 | micturitions per 24 hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04641975/results